Float Short %

5.57

Margin Of Safety %

Put/Call OI Ratio

2.09

EPS Next Q Diff

-0.05

EPS Last/This Y

4.11

EPS This/Next Y

0.13

Price

43.85

Target Price

58.07

Analyst Recom

2.2

Performance Q

19.46

Relative Volume

1.28

Beta

0.62

Ticker: PTCT

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	PTCT	45.2	2.61	2.85	15795
2024-12-20	PTCT	46.2	2.57	9.05	15826
2024-12-23	PTCT	45.54	2.38	4.80	9124
2024-12-24	PTCT	45.35	2.37	0.57	9172
2024-12-26	PTCT	45.86	2.33	0.55	9236
2024-12-27	PTCT	45.24	2.30	0.54	9286
2024-12-30	PTCT	45.74	2.27	21.00	9345
2024-12-31	PTCT	45.13	2.27	4.67	9340
2025-01-02	PTCT	45.87	2.28	1.19	9352
2025-01-03	PTCT	46.49	2.27	0.43	9366
2025-01-06	PTCT	45.84	2.24	2.00	9415
2025-01-07	PTCT	44.57	2.23	0.71	9427
2025-01-08	PTCT	45.01	2.23	999.99	9431
2025-01-09	PTCT	45.04	2.23	999.99	9431
2025-01-10	PTCT	44.06	2.23	1.60	9433
2025-01-13	PTCT	44.02	2.23	0.91	9436
2025-01-14	PTCT	41.86	2.22	1.40	9439
2025-01-15	PTCT	42.21	2.22	13.67	9450
2025-01-16	PTCT	43.1	2.11	999.99	9352
2025-01-17	PTCT	43.92	2.09	0.20	9311
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	PTCT	45.22	-240.2	1225.8	-4.26
2024-12-20	PTCT	46.22	-240.2	1258.9	-4.26
2024-12-23	PTCT	45.56	-234.4	1216.4	-4.26
2024-12-24	PTCT	45.35	-234.4	1228.1	-4.26
2024-12-26	PTCT	45.84	-234.4	1246.5	-4.26
2024-12-27	PTCT	45.27	-234.4	1219.0	-4.26
2024-12-30	PTCT	45.71	-234.4	1246.3	-4.26
2024-12-31	PTCT	45.12	-234.4	1217.0	-4.26
2025-01-02	PTCT	45.89	-234.4	1253.4	-4.26
2025-01-03	PTCT	46.50	-234.4	1249.7	-4.26
2025-01-06	PTCT	45.82	-234.4	1215.5	-4.26
2025-01-07	PTCT	44.58	-234.4	1202.6	-4.26
2025-01-08	PTCT	45.04	-234.4	1245.1	-4.26
2025-01-09	PTCT	45.04	-234.4	1233.6	-4.26
2025-01-10	PTCT	43.94	-234.4	1204.5	-4.26
2025-01-13	PTCT	44.10	-234.4	1237.9	-4.26
2025-01-14	PTCT	41.87	-234.4	1174.7	-4.26
2025-01-15	PTCT	42.27	-234.4	1246.9	-4.26
2025-01-16	PTCT	43.06	-234.4	1256.3	-4.26
2025-01-17	PTCT	43.85	-232.6	1255.1	-4.26
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	PTCT	-7.37	-1.63	6.17
2024-12-20	PTCT	-7.37	-1.63	6.17
2024-12-23	PTCT	-7.22	-1.63	6.17
2024-12-24	PTCT	-7.22	-1.63	6.17
2024-12-26	PTCT	-7.40	-1.63	6.16
2024-12-27	PTCT	-7.57	-1.63	6.16
2024-12-30	PTCT	-7.46	-1.61	6.16
2024-12-31	PTCT	-7.46	-1.61	6.16
2025-01-02	PTCT	-7.46	-1.61	6.16
2025-01-03	PTCT	-7.37	-1.61	6.16
2025-01-06	PTCT	-7.53	-1.63	6.16
2025-01-07	PTCT	-7.53	-1.63	6.16
2025-01-08	PTCT	-7.63	-1.63	6.16
2025-01-09	PTCT	-7.63	-1.63	6.16
2025-01-10	PTCT	-7.63	-1.63	6.18
2025-01-13	PTCT	-7.81	-1.63	5.57
2025-01-14	PTCT	-12.09	-1.63	5.57
2025-01-15	PTCT	-12.09	-1.63	5.57
2025-01-16	PTCT	-12.09	-1.63	5.57
2025-01-17	PTCT	-12.23	-1.63	5.57
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-1.39

Avg. EPS Est. Current Quarter

-0.97

Avg. EPS Est. Next Quarter

-1.44

Insider Transactions

-12.23

Institutional Transactions

-1.63

Beta

0.62

Average Sales Estimate Current Quarter

214

Average Sales Estimate Next Quarter

480

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

38.1

Max Drawdown 5-Year %

-73.8

Target Price

58.07

P/E

Forward P/E

PEG

P/S

3.75

P/B

P/Free Cash Flow

EPS

-5.94

Average EPS Est. Cur. Y

-4.26

EPS Next Y. (Est.)

-4.12

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-50.32

Relative Volume

1.28

Return on Equity vs Sector %

23.9

Return on Equity vs Industry %

36.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.04

EBIT Estimation

1255.1

PTC Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 988

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

stock quote shares PTCT – PTC Therapeutics Inc Stock Price stock today

news today PTCT – PTC Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch PTCT – PTC Therapeutics Inc yahoo finance google finance

stock history PTCT – PTC Therapeutics Inc invest stock market

stock prices PTCT premarket after hours

ticker PTCT fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: PTCT

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y